Monopar Therapeutics Inc. (NASDAQ: MNPR) presented new analyses from its Phase 3 FoCus trial showing ALXN1840 provided greater neurologic benefit ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA